Base de datos : IBECS
Búsqueda : "1699-048X" [ISSN]
Referencias encontradas : 1931 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 194 va a la página                         

  1 / 1931 IBECS  
              next record last record
selecciona
para imprimir
Id: 171649
Autor: Abdel-Rahman, O.
Título: Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer
Fuente: Clin. transl. oncol. (Print);20(4):550-556, abr. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-017-1739-6.
Resumen: Background. The current study tried to validate the prognostic significance of the 8th American Joint Committee on Cancer (AJCC) staging system among small cell lung cancer (SCLC) patients recorded within the surveillance, epidemiology, and end results (SEER) database. Patients and methods. SEER database (2004û2014) has been queried through SEER*Stat program, and both AJCC 7th and 8th edition stages were constructed. Cancer-specific and overall survival analyses according to both editions were performed through KaplanûMeier analysis. The cause-specific Cox regression hazard for both AJCC editions (adjusted for age, gender, race, and surgery) was calculated and pair-wise comparisons of hazard ratios were conducted. Results. A total of 39,286 patients with SCLC were recruited in the period from 2004 to 2014. For overall and cancer-specific survival assessment, according to the AJCC 7th edition, P values for all pair-wise comparisons among different stages were significant (<0.0001) except for the comparisons between stage IB vs. stage IIA, and stage IIB vs. stage IIIA. For overall survival assessment, according to AJCC 8th, P values for all pair-wise comparisons were significant (<0.05) except for IA2 vs. IA3, IA3 vs. IB, IB vs. IIA, IIA vs. IIB, and IIIB vs. IIIC. For cancer-specific survival, according to AJCC 8th, P values for all pair-wise comparisons among different stages were significant (<0.05) except IA1 vs. IA2, IA2 vs. IA3, and IIA vs. IIB. When conducting pair-wise hazard ratio comparisons among different AJCC stages (for both editions), similar findings to the KaplanûMeier analyses were reported. Conclusion. While there is a clear improvement for both the AJCC 7th and 8th systems compared to the old veterans' administration system, there is a modest improvement for the 8th compared to the 7th system among patients with SCLC (AU)

No disponible
Descriptores: neoplasias pulmonares/clasificación
carcinoma de células pequeñas/clasificación
estadificación de neoplasias/métodos
-tasa de supervivencia
marcadores tumorales/análisis
Clasificación Internacional de Enfermedades/instrumentación
Límites: humanos
Responsable: BNCS


  2 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171648
Autor: Carrara, R de Cássia Viu; Fontes, AM; Abraham, KJ; Orellana, MD; Haddad, SK; Palma, PVB; Panepucci, RA; Zago, MA; Covas, DT.
Título: Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls
Fuente: Clin. transl. oncol. (Print);20(4):542-549, abr. 2018. tab, ilus, graf.
Idioma: en.
doi: 10.1007/s12094-017-1751-x.
Resumen: Purpose. The fusion gene BCR-ABL has an important role to the progression of chronic myeloid leukemia (CML) and several signaling pathways have been characterized as responsible for the terminal blastic phase (BP). However, the initial phase, the chronic phase (CP), is long lasting and there is much yet to be understood about the critical role of BCR-ABL in this phase. This study aims to evaluate transcriptional deregulation in CD34+ hematopoietic cells (CD34+ cells) from patients with untreated newly diagnosed CML compared with CD34+HC from healthy controls. Methods. Gene expression profiling in CML-CD34 cells and CD34 cells from healthy controls were used for this purpose with emphasis on five main pathways important for enhanced proliferation/survival, enhanced self-renewal and block of myeloid differentiation. Results. We found 835 genes with changed expression levels (fold change ≥ ±2) in CML-CD34 cells compared with CD34 cells. These include genes belonging to PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways. Four of these pathways converge to MYC activation. We also identified five transcripts upregulated in CD34-CML patients named OSBPL9, MEK2, p90RSK, TCF4 and FZD7 that can be potential biomarkers in CD34-CML-CP. Conclusion. We show several mRNAs up- or downregulated in CD34-CML during the chronic phase (AU)

No disponible
Descriptores: antígenos CD34/análisis
células madre hematopoyéticas/patología
receptores Notch/análisis
sistema de señalización de las MAP cinasas/fisiología
leucemia mielogenosa crónica BCR-ABL positiva/patología
-estudios de casos y controles
proteínas protooncogénicas c-akt/fisiología
perfiles de expresión génica/métodos
ARN mensajero/análisis
Límites: humanos
Responsable: BNCS


  3 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171647
Autor: Liu, X; Qiu, Z; Wang, Z; Zuo, W; Gong, Z; Liu, C; Zeng, Q; Qian, Y; Jiang, L; Li, Y; Bu, Y; Hu, G.
Título: NFBD1/MDC1 participates in the regulation of proliferation and apoptosis in human laryngeal squamous cell carcinoma
Fuente: Clin. transl. oncol. (Print);20(4):534-541, abr. 2018. tab, ilus, graf.
Idioma: en.
doi: 10.1007/s12094-017-1748-5.
Resumen: Purpose. The objective of the study was to investigate the role of NFBD1 in the proliferation and apoptosis of laryngeal squamous cell carcinoma (LSCC) cells. Methods. Immunohistochemistry (IHC) and qRT-PCR was employed to determine the expressions of NFBD1 protein and mRNA in LSCC tissues and adjacent noncancerous tissues. After the downregulation of NFBD1 expression, the colony formation assay, MTS assay and apoptosis assay were used to investigate the changes in the proliferation and apoptosis of Hep2 cells. The mechanisms by which silencing NFBD1 promote apoptosis of Hep2 cells were examined by western blotting. Furthermore, xenograft models were used to evaluate the proliferation of Hep2 cells in vivo. Results. NFBD1 protein was upregulated in 55.6% of LSCC cancer tissues compared with adjacent normal tissues (26.7%). NFBD1 knockdown in Hep2 cells significantly impacted proliferation and apoptosis, and silencing NFBD1 might promote apoptosis of Hep2 cells by activating the mitochondrial apoptotic pathway. Xenograft models showed that silencing NFBD1 also significantly inhibited tumor growth. Conclusions. Our data highlight that NFBD1 participates in the regulation of proliferation and apoptosis in LSCC, and suggest that NFBD1 could be a promising therapy target (AU)

No disponible
Descriptores: carcinoma de células escamosas/patología
neoplasias laríngeas/patología
proteína 1 de unión al supresor tumoral p53/fisiología
daño del ADN/fisiología
-proliferación celular/fisiología
apoptosis/fisiología
inmunohistoquímica
ciclo celular/fisiología
marcadores tumorales/análisis
Límites: humanos
Responsable: BNCS


  4 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171646
Autor: Yu, Ying-hua; Zhu, Xiao; Mo, Qin-guo; Cui, Ying.
Título: Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer
Fuente: Clin. transl. oncol. (Print);20(4):524-533, abr. 2018. tab, graf, ilus.
Idioma: en.
doi: 10.1007/s12094-017-1745-8.
Resumen: Purpose. Near-infrared diffuse optical spectroscopy (DOS) has been recently used to predict neoadjuvant chemotherapy response (NAC). In the present study, we explore the change in blood-oxygen content using DOS to predict NAC response against breast cancer. Materials and methods. A total of 20 patients were enrolled and underwent DOS scan with blood-oxygen detection before each treatment cycle. The first DOS scan was performed before NAC treatment (pretreatment), and subsequent scans were performed after each NAC treatment circle. Changes in blood content and oxygen content by DOS were evaluated and compared with tumor size, and their changes were analyzed in response versus nonresponse group. Results. Thirteen patients were classified into response and seven patients into nonresponse group. The tumor blood content value (−1.06 ± 0.43) and oxygen content value (0.48 ± 0.17) of DOS at pretreatment was significantly different from presurgery in response group (P < 0.05), but not in nonresponse group. In response group, the percentage change in blood content (median 91.19%) was significantly larger than tumor size (median 48.89%) (P = 0.0035), while in oxygen content (median 47.11%) is not (P = 0.2815). Comparing each cycle, the percentage change in blood content could distinguish responder from non-responder as early as after the first treatment cycle (19.1 versus 6.6%, P = 0.0265). Blood content percentage sensitivity was 76.9% and specificity was 85.7% (AUC 0.912), while oxygen content percentage sensitivity was 76.9% and specificity was 71.4% (AUC 0.797). Conclusion. Both blood and oxygen content measured by DOS could be used to discriminate responder to the treatment versus non-responder. Among the two, percentage change of blood content was more precise and earlier than that of oxygen content to predicted breast tumor response. The percentage change in blood content could distinguish responder from non-responder after the first treatment cycle (AU)

No disponible
Descriptores: neoplasias de la mama/tratamiento farmacológico
tratamiento neoadyuvante/métodos
espectroscopia infrarroja cercana/métodos
-pronóstico
sensibilidad y especificidad
neoplasias de la mama/patología
tratamientos preservadores de órganos/utilización
mastectomía/métodos
marcadores tumorales/análisis
Límites: humanos
femenino
adulto
mediana edad
Responsable: BNCS


  5 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171645
Autor: Padilla-Iserte, P; Minig, L; Zapardiel, I; Chiva, L; Laky, R; Santiago, J de.
Título: Current situation in gynecological oncology training in Spain: where we are and where we want to go
Fuente: Clin. transl. oncol. (Print);20(4):517-523, abr. 2018. tab.
Idioma: en.
doi: 10.1007/s12094-017-1744-9.
Resumen: Background. It is important to know what a young gynecologic oncologist perceives as a need to achieve a good training in gynecologic oncology. Objective. This study aims to evaluate the level of training in gynecologic oncology in Spain. Methods. A Web-based anonymous questionnaire was sent via e-mail to Spanish trainees listed in European Network of Young Gynecological Oncology (ENYGO). The survey was developed in four sections: (1) general training in gynecologic oncology, (2) distribution of current clinical activity, (3) surgical training, and (4) perspective future gynecologic oncology. It contained 51 questions, with multiple-choice answers that had to be answered by the ENYGO members. Results. The questionnaire was sent to 64 people listed in the ENYGO database. Of these, 37 members responded (response rate of 58%). Overall, more training in surgery is necessary, to perform radical oncological surgeries. It is claimed a sub-specialty recognition, to ensure an equalitarian and homogeneous training (AU)

No disponible
Descriptores: oncología médica/educación
ginecología/educación
educación médica continuada/tendencias
-necesidades y demandas de servicios de salud/tendencias
evaluación de la enseñanza
encuestas sobre atención a la salud/estadística & datos numéricos
programa de estudios
Límites: humanos
Responsable: BNCS


  6 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171644
Autor: Stritzelberger, J; Distel, L; Buslei, R; Fietkau, R; Putz, F.
Título: Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine
Fuente: Clin. transl. oncol. (Print);20(4):508-516, abr. 2018. graf, ilus.
Idioma: en.
doi: 10.1007/s12094-017-1743-x.
Resumen: Purpose. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. While the alkylating agent temozolomide (TMZ) has prolonged overall survival, resistance evolution represents an important clinical problem. Therefore, we studied the effectiveness of radiotherapy and CCNU in an in vitro model of acquired TMZ resistance. Methods. We studied the MGMT-methylated GBM cell line U251 and its in vitro derived TMZ-resistant subline, U251/TMZ-R. Cytotoxicity of TMZ, CCNU, and radiation was tested. Both cell lines were analyzed for MGMT promotor status and expression of mismatch repair genes (MMR). The influence of MMR inhibition by cadmium chloride (CdCl2) on the effects of both drugs was evaluated. Results. During the resistance evolution process in vitro, U251/TMZ-R developed MMR deficiency, but MGMT status did not change. U251/TMZ-R cells were more resistant to TMZ than parental U251 cells (cell viability: 92.0% in U251/TMZ-R/69.2% in U251; p = 0.032) yet more sensitive to CCNU (56.4%/80.8%; p = 0.023). The effectiveness of radiotherapy was not reduced in the TMZ-resistant cell line. Combination of CCNU and TMZ showed promising results for both cell lines and overcame resistance. CdCl2-induced MMR deficiency increased cytotoxicity of CCNU. Conclusion. Our results confirm MMR deficiency as a crucial process for resistance evolution to TMZ. MMR-deficient TMZ-resistant GBM cells were particularly sensitive to CCNU and to combined CCNU/TMZ. Effectiveness of radiotherapy was preserved in TMZ-resistant cells. Consequently, CCNU might be preferentially considered as a treatment option for recurrent MGMT-methylated GBM and may even be suitable for prevention of resistance evolution in primary treatment (AU)

No disponible
Descriptores: glioblastoma/tratamiento farmacológico
resistencia a los antineoplásicos
neoplasias cerebrales/tratamiento farmacológico
-lomustina/farmacocinética
línea celular tumoral/efectos de drogas
reparación del emparejamiento incorrecto del ADN
Límites: humanos
Responsable: BNCS


  7 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171643
Autor: Mora, J; Perez-Jaume, S; Cruz, O.
Título: Treatment of childhood astrocytomas with irinotecan and cisplatin
Fuente: Clin. transl. oncol. (Print);20(4):500-507, abr. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-017-1741-z.
Resumen: Background. Previously we described the outcome of children with spinal cord astrocytoma treated with irinotecan and cisplatin (I/C). We here report the review of the initial institutional experience using this combination for children with low-grade glioma (LGG). Procedure. I/C chemotherapy consisted of weekly cisplatin (30 mg/m2) and irinotecan (50û65 mg/m2) for a total maximum of 16 doses, administered in an outpatient basis. Results. Between November 2002 and December 2009, 46 children (median age 6.3 years; range 0.3û17.7) with glioma were treated. We here report the cohort of 31 patients with LGG. Patients received a median of 16 cycles of I/C (range 8û16). The overall objective response [complete response (CR) + partial response (PR)] and disease control (CR + PR + stable disease) rates to I/C treatment were 6.5% [95% confidence interval (CI), 0.8û21.4%] and 93.5% (95% CI 78.6û99.2%), respectively. Disease control persisted for a median of 65 months. Toxicity was predominantly myelosuppression only seen in heavily pretreated patients. Survival analysis shows 5-year event-free survival (EFS) of 54% and 5-year overall survival (OS) of 80%. Conclusion. I/C chemotherapy produced disease control and clinical improvement in a majority of children with low-grade glioma, with manageable toxicity (AU)

No disponible
Descriptores: astrocitoma/tratamiento farmacológico
cisplatino/uso terapéutico
neoplasias de la médula espinal/tratamiento farmacológico
-antineoplásicos/uso terapéutico
glioma/tratamiento farmacológico
glioblastoma/tratamiento farmacológico
Límites: humanos
niño
Responsable: BNCS


  8 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171642
Autor: Zhao, Z; Xu, Y; Lu, J; Xue, J; Liu, P.
Título: High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells
Fuente: Clin. transl. oncol. (Print);20(4):491-499, abr. 2018. tab, ilus, graf.
Idioma: en.
doi: 10.1007/s12094-017-1738-7.
Resumen: Purpose. HO-1 has been proved to be associated with tumor aggressivity and poor prognosis in various cancers. Our study provides the first study to demonstrate the relationship of HO-1 expression and clinical characteristics in ovarian cancer patients. Methods. Immunohistochemistry and western blotting were used to examine the expression of HO-1 in tissue species and fresh tissues. CCK-8 was used to investigate cell viability. Transwell chamber was performed to estimate migration and invasion capacities in A2780 and Skov-3 cells. Results. Immunohistochemistry and western blotting showed that the expression of HO-1 was higher in ovarian cancer tissues than normal ovarian tissues. High expression of HO-1 was significantly associated with serous ovarian cancer, high FIGO stage, lymph node metastasis, and non-optimal debulking. Patients with high expression of HO-1 exhibited an unfavorable prognosis. In vitro inducing the expression of HO-1 promoted the proliferation and metastasis of A2780 and Skov-3 cells, with the increased expressions of mesenchymal marker (Vimentin), epithelialûmesenchymal transition-associated transcript factor (Zeb-1), anti-apoptotic protein (Bcl-2), and the decreased expressions of epithelial marker (Keratin) and pro-apoptotic protein (Bax). Meanwhile, after incubating A2780 and Skov-3 together with HO-1 inhibitor, above results could be reversed. Conclusion. HO-1 might be a potential marker for prediction of ovarian cancer prognosis and a target for ovarian cancer treatment (AU)

No disponible
Descriptores: neoplasias ováricas/patología
proliferación celular/fisiología
hemo oxigenasa 1/análisis
-marcadores tumorales/análisis
metástasis neoplásica/patología
pronóstico
Límites: humanos
femenino
Responsable: BNCS


  9 / 1931 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 171641
Autor: Guler, OC; Engels, B; Onal, C; Everaert, H; Begin, R van den; Gevaert, T; Ridder, M de.
Título: The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients
Fuente: Clin. transl. oncol. (Print);20(4):484-490, abr. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-017-1736-9.
Resumen: Background. To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC (68Ga-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively. Methods. A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on ≤3 metastases detected by 68Ga PSMA PET-CT. Androgen deprivation therapy was continued in CR patients. Results. A total of 38 metastases were treated. The involved sites were pelvic bone (n = 16), pelvic lymph nodes (n = 11), paraaortic lymph nodes (n = 6), ribs (n = 3) and vertebral body (n = 2). The median PSA prior to RT was 1.1 ng/mL (range 0.1û29.0 ng/mL). A median dose of 43.5 Gy (range 30û64 Gy) was delivered by IMRT-IGRT in 12û27 fractions. At a median follow-up of 7 months (range 2û17 months), 19 patients (83%) were in remission. Four patients (17%) developed distant recurrences. The actuarial 1-year LC, PFS and OS rates were 100, 51 (95% CI 8û83%) and 100%. Univariate analysis demonstrated a statistically significantly better PFS in CS patients as compared to CR patients (1-year PFS 67 vs. 0%, p < 0.01). One patient experienced grade 2 acute gastrointestinal toxicity. Grade 3 or more toxicity events were not observed. Conclusions. By providing optimal LC, low toxicity and a promising PFS in CS patients, the current retrospective study illustrated that 68Ga PSMA PET-CT-guided RT may be an attractive treatment strategy in patients with oligometastatic prostate cancer. Validation by randomized trials is eagerly awaited (AU)

No disponible
Descriptores: neoplasias de la próstata/radioterapia
antígeno prostático específico/análisis
neoplasias prostáticas resistentes a la castración/radioterapia
-tomografía por emisión de positrones-tomografía computarizada/métodos
metástasis neoplásica/radioterapia
Límites: humanos
masculino
Responsable: BNCS


  10 / 1931 IBECS  
              first record previous record
selecciona
para imprimir
Id: 171640
Autor: Marín Hernández, C; Piñero Madrona, A; Gil Vázquez, PJ; Galindo Fernández, PJ; Ruiz Merino, G; Alonso Romero, JL; Parrilla Paricio, P.
Título: Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy
Fuente: Clin. transl. oncol. (Print);20(4):476-483, abr. 2018. tab, graf.
Idioma: en.
doi: 10.1007/s12094-017-1732-0.
Resumen: Background. Nowadays, neoadjuvant chemotherapy (nCT) in breast cancer is more and more standardized, not only in advanced tumours but also in those for which there is an attempt to achieve breast-conserving surgery. In literature, we can find evidences of the relationship between several types of tumours and systemic inflammatory response. Our objective is to analyse the prognostic value of blood parameters (lymphocytes, neutrophils, monocytes, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer (BC) patients treated with nCT. Methods. A retrospective cohort of 150 breast cancer patients treated with nCT and subsequently with surgery was analysed. Data about the patients, histology, response to chemotherapy and peripheral blood values of lymphocytes, monocytes and neutrophils was collected, and used to calculate the LMR, NMR and NLR. Univariate and multivariate analyses were performed for the variables to see the relationship of the ratios to disease-free survival (DFS) and overall survival (OS). Results. Patients with high LMR (≥5.46) and low NLR (<3.33) were associated with a lower percentage of relapse (P = 0.048 and P = 0.015, respectively) and, above all, NLR was associated with a better survival (P = 0.024), being those factors that predict a good progress. Conclusion. High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT (AU)

No disponible
Descriptores: neoplasias de la mama/patología
antineoplásicos/farmacocinética
linfocitos/efectos de drogas
monocitos/efectos de drogas
neutrófilos/efectos de drogas
-neoplasias de la mama/tratamiento farmacológico
tratamiento neoadyuvante/estadística & datos numéricos
estudios retrospectivos
marcadores tumorales/análisis
pronóstico
Límites: humanos
femenino
Responsable: BNCS



página 1 de 194 va a la página                         
   


Refinar la búsqueda
  Base de datos : IBECS Formulario avanzado   
Buscar por : Formulario libre    Formulario básico

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud